LncRNA MEG3 has anti-activity effects of cervical cancer.

Aim: The aim of this study was to explain the lncRNA MEG3 had anti-cancer effects to suppress cervical carcinoma biological activity. Methods: The Hela cell were divided into three groups (NC group, BL group and lncRNA group). The cells of lncRNA or BL groups were transfered with lncRNA MEG3 or blank carrier. Evaluating the cell proliferation rate of difference groups by MTT assay; measuring the cell apoptosis and cell cycle of difference groups' cell by flow-cytometry; the cell invasion activity of difference groups were measured by transwell assay, the cell migration ability of difference groups were evaluated by wound healing testing. Measuring the relative gene expressions (PI3K, AKT, MMP-2, MMP-9, Bcl-2, Bax and P21) and protein expressions (PI3K, AKT, p-AKT, MMP-2, MMP-9, Bcl-2, Bax and P21) by RT-PCR or WB assay. Results: Compared with NC group, The cell proliferation rate of lncRNA group was significantly reduced (P < 0.05) and the cell apoptosis and G1 phase were significantly increased (P < 0.05, respectively). The invasion cell of lncRNA MEG3 group were significantly difference compared with NC group (P < 0.05), and the wound healing rate of lncRNA MEG3 group was significantly shorter than NC group (P < 0.05). The PI3K, AKT, MMP-2, MMP-9 and Bcl-2 gene expression of lncRNA group were significanlty down-regulation compared with NC group (P < 0.05, respectively), and Bax and P21 gene expression of lncRNA group were significantly up-regulation compared with NC group (P < 0.05, respectively) by RT-PCR testing. The PI3K, AKT, p-AKT, MMP-2, MMP-9 and Bcl-2 protein expression of lncRNA group were significanlty down-regulation compared with NC group (P < 0.05, respectively), and Bax and P21 protein expression of lncRNA group were significantly up-regulation compared with NC group (P < 0.05, respectively) by WB assay. Conclusion: The lncRNA MEG3 had effects to supress cervical cancer by regulation PI3K/AKT/Bcl-2/Bax/P21 and PI3K/AKT/MMP-2/9 signaling pathway. (C) 2017 Elsevier Masson SAS. All rights reserved.